| Gothenburg (N=424) |
Northern (N=493) |
Stockholm CFN Karolinska (N=1445) |
Stockholm Danderyd (N=328) |
Overall (N=2690) |
|
|---|---|---|---|---|---|
| Sex | |||||
| Female | 282 (66.5%) | 330 (66.9%) | 995 (68.9%) | 232 (70.7%) | 1839 (68.4%) |
| Male | 142 (33.5%) | 162 (32.9%) | 449 (31.1%) | 96 (29.3%) | 849 (31.6%) |
| Missing | 0 (0%) | 1 (0.2%) | 1 (0.1%) | 0 (0%) | 2 (0.1%) |
| Age | |||||
| Mean (SD) | 43.5 (12.3) | 40.7 (11.6) | 42.0 (11.6) | 41.7 (10.8) | 41.9 (11.6) |
| Median [Min, Max] | 43.0 [9.70, 74.6] | 40.8 [13.5, 75.1] | 41.8 [14.4, 77.7] | 41.7 [15.7, 69.6] | 41.9 [9.70, 77.7] |
| Missing | 0 (0%) | 1 (0.2%) | 2 (0.1%) | 0 (0%) | 3 (0.1%) |
| BMI | |||||
| Mean (SD) | 25.6 (4.94) | 27.4 (6.94) | 25.3 (5.11) | 25.8 (5.47) | 25.7 (5.46) |
| Median [Min, Max] | 24.7 [17.5, 46.6] | 25.2 [16.3, 49.8] | 24.3 [14.5, 61.6] | 25.2 [13.7, 49.9] | 24.6 [13.7, 61.6] |
| Missing | 252 (59.4%) | 288 (58.4%) | 478 (33.1%) | 111 (33.8%) | 1129 (42.0%) |
| MS type | |||||
| NA | 1 (0.2%) | 0 (0%) | 2 (0.1%) | 1 (0.3%) | 4 (0.1%) |
| PPMS | 38 (9.0%) | 28 (5.7%) | 72 (5.0%) | 6 (1.8%) | 144 (5.4%) |
| RRMS | 278 (65.6%) | 381 (77.3%) | 1007 (69.7%) | 266 (81.1%) | 1932 (71.8%) |
| SPMS | 107 (25.2%) | 84 (17.0%) | 364 (25.2%) | 55 (16.8%) | 610 (22.7%) |
| EDSS | |||||
| Mean (SD) | 3.09 (2.14) | 2.17 (1.89) | 2.83 (1.94) | 2.10 (1.74) | 2.68 (1.98) |
| Median [Min, Max] | 2.50 [0, 8.75] | 2.00 [0, 8.00] | 2.50 [0, 8.75] | 1.75 [0, 9.00] | 2.00 [0, 9.00] |
| Missing | 55 (13.0%) | 186 (37.7%) | 280 (19.4%) | 38 (11.6%) | 559 (20.8%) |
| Previous treatment | |||||
| Cladribine | 2 (0.5%) | 4 (0.8%) | 12 (0.8%) | 2 (0.6%) | 20 (0.7%) |
| Dimethyl_fumarate | 13 (3.1%) | 10 (2.0%) | 45 (3.1%) | 11 (3.4%) | 79 (2.9%) |
| Fingolimod | 16 (3.8%) | 13 (2.6%) | 42 (2.9%) | 5 (1.5%) | 76 (2.8%) |
| Glatiramer_acetate | 17 (4.0%) | 9 (1.8%) | 50 (3.5%) | 6 (1.8%) | 82 (3.0%) |
| Interferon | 73 (17.2%) | 78 (15.8%) | 203 (14.0%) | 62 (18.9%) | 416 (15.5%) |
| Natalizumab | 149 (35.1%) | 146 (29.6%) | 510 (35.3%) | 95 (29.0%) | 900 (33.5%) |
| Other | 11 (2.6%) | 7 (1.4%) | 44 (3.0%) | 13 (4.0%) | 75 (2.8%) |
| Other Anti-CD20 | 7 (1.7%) | 12 (2.4%) | 28 (1.9%) | 4 (1.2%) | 51 (1.9%) |
| Teriflunomide | 3 (0.7%) | 5 (1.0%) | 4 (0.3%) | 1 (0.3%) | 13 (0.5%) |
| treatment_naive | 133 (31.4%) | 209 (42.4%) | 507 (35.1%) | 129 (39.3%) | 978 (36.4%) |
| IgG | |||||
| Mean (SD) | 9.59 (2.23) | 9.56 (2.17) | 10.0 (2.18) | 9.78 (2.06) | 9.84 (2.18) |
| Median [Min, Max] | 9.40 [2.30, 17.0] | 9.41 [4.26, 19.0] | 9.85 [3.20, 20.6] | 9.69 [4.98, 16.3] | 9.68 [2.30, 20.6] |
| Missing | 5 (1.2%) | 5 (1.0%) | 10 (0.7%) | 0 (0%) | 20 (0.7%) |
| Neutrophils | |||||
| Mean (SD) | 4.17 (1.27) | 4.02 (1.16) | 4.10 (1.37) | 3.85 (1.17) | 4.07 (1.30) |
| Median [Min, Max] | 3.95 [1.12, 11.4] | 3.90 [1.83, 9.38] | 3.88 [1.22, 15.2] | 3.74 [1.03, 10.0] | 3.87 [1.03, 15.2] |